GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Globus Medical Inc (NYSE:GMED) » Definitions » Altman Z2-Score

Globus Medical (Globus Medical) Altman Z2-Score : 6.77 (As of Apr. 28, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Globus Medical Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Good Sign:

Globus Medical has a Altman Z2-Score of 6.77, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Globus Medical's Altman Z2-Score or its related term are showing as below:

GMED' s Altman Z2-Score Range Over the Past 10 Years
Min: 6.77   Med: 14.09   Max: 16.89
Current: 6.77

During the past 13 years, Globus Medical's highest Altman Z2-Score was 16.89. The lowest was 6.77. And the median was 14.09.


Globus Medical Altman Z2-Score Historical Data

The historical data trend for Globus Medical's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Globus Medical Altman Z2-Score Chart

Globus Medical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.89 14.40 13.51 13.78 6.77

Globus Medical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.78 14.08 15.07 6.66 6.77

Competitive Comparison of Globus Medical's Altman Z2-Score

For the Medical Devices subindustry, Globus Medical's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Globus Medical's Altman Z2-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Globus Medical's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Globus Medical's Altman Z2-Score falls into.



Globus Medical Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Globus Medical's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*0.2994+3.26*0.2236+6.72*0.033+1.05*3.6742
=6.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Dec. 2023:
Total Assets was $5,086 Mil.
Total Current Assets was $1,915 Mil.
Total Current Liabilities was $392 Mil.
Retained Earnings was $1,137 Mil.
Pre-Tax Income was 24.994 + 2.535 + 74.674 + 63.189 = $165 Mil.
Interest Expense was -2.581 + 0 + 0 + 0 = $-3 Mil.
Total Liabilities was $1,088 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(1915.374 - 392.347)/5086.083
=0.2994

X2=Retained Earnings/Total Assets
=1137.266/5086.083
=0.2236

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(165.392 - -2.581)/5086.083
=0.033

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(3997.959 - 0)/1088.124
=3.6742

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Globus Medical has a Altman Z2-Score of 6.77 indicating it is in Safe Zones.


Globus Medical  (NYSE:GMED) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Globus Medical Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Globus Medical's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Globus Medical (Globus Medical) Business Description

Traded in Other Exchanges
Address
2560 General Armistead Avenue, Audubon, PA, USA, 19403
Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.
Executives
Leslie V Norwalk director C/O 3661 VALLEY CENTRE DRIVE SUITE 200, SAN DIEGO CA 92130
Dan Wolterman director 3721 VALLEY CENTRE DR, SUITE 500, SAN DIEGO CA 92130
John A Deford director C R BARD INC, 730 CENTRAL AVENUE, MURRAY HILL NJ 07974
Dan Lemaitre director 2 MUSICK, IRVINE CA 92618
Keith W Pfeil officer: SVP, Chief Financial Officer GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Kelly Huller officer: SVP, General Counsel 2560 GENERAL ARMISTEAD AVENUE, AUDOBON PA 19403
David D Davidar director, officer: Vice President, Operations C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
James R Tobin director C/O CURIS INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Daniel T Scavilla officer: Senior VP and CFO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David M Demski director, officer: President and COO C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Robert Andrew Douglas director 21 ATTUNGA ROAD, NEWPORT, NEW SOUTH WALES C3 2106
Stephen T Zarrilli director FIBERLINK COMMUNICATIONS CORP., 794 PENLLYN PIKE, BLUE BELL PA 19422
Anthony L Williams officer: Senior VP of Bus. Devel. & GC C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
Steven Payne officer: Chief Accounting Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403
David C Paul director, 10 percent owner, officer: Chief Executive Officer C/O GLOBUS MEDICAL, INC., 2560 GENERAL ARMISTEAD AVENUE, AUDUBON PA 19403